» Articles » PMID: 10906907

Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group

Overview
Journal CMAJ
Date 2000 Jul 25
PMID 10906907
Citations 146
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To provide physicians with current guidelines for the diagnosis and optimal management of asthma in children and adults, including pregnant women and the elderly, in office, emergency department, hospital and clinic settings.

Options: The consensus group considered the roles of education, avoidance of provocative environmental and other factors, diverse pharmacotherapies, delivery devices and emergency and in-hospital management of asthma.

Outcomes: Provision of the best control of asthma by confirmation of the diagnosis using objective measures, rapid achievement and maintenance of control and regular follow-up.

Evidence: The key diagnostic and therapeutic recommendations are based on the 1995 Canadian guidelines and a critical review of the literature by small groups before a full meeting of the consensus group. Recommendations are graded according to 5 levels of evidence. Differences of opinion were resolved by consensus following discussion.

Values: Respirologists, immunoallergists, pediatricians and emergency and family physicians gave prime consideration to the achievement and maintenance of optimal control of asthma through avoidance of environmental inciters, education of patients and the lowest effective regime of pharmacotherapy to reduce morbidity and mortality.

Benefits, Harms And Costs: Adherence to the guidelines should be accompanied by significant reduction in patients' symptoms, reduced morbidity and mortality, fewer emergency and hospital admissions, fewer adverse side-effects from medications, better quality of life for patients and reduced costs.

Recommendations: Recommendations are included in each section of the report. In summary, after a diagnosis of asthma is made based on clinical evaluation, including demonstration of variable airflow obstruction, and contributing factors are identified, a treatment plan is established to obtain and maintain optimal asthma control. The main components of treatment are patient education, environmental control, pharmacotherapy tailored to the individual and regular follow-up.

Validation: The recommendations were distributed to the members of the Canadian Thoracic Society Asthma and Standards Committees, as well as members of the board of the Canadian Thoracic Society. In addition, collaborating groups representing the Canadian Association of Emergency Physicians, the Canadian College of Family Physicians, the Canadian Paediatric Society and the Canadian Society of Allergy and Immunology were asked to validate the recommendations. The recommendations were discussed at regional meetings throughout Canada. They were also compared with the recommendations of other similar groups in other countries. DISSEMINATION AND IMPLEMENTATION: An implementation committee has established a strategy for disseminating these guidelines to physicians, other health professionals and patients and for developing tools and means that will help integrate the recommendations into current asthma care. The plan is outlined in this report.

Citing Articles

Inhaled corticosteroid increased the risk of adrenal insufficiency in patients with chronic airway diseases: a nationwide population-based study.

Lee H, Yoon H Sci Rep. 2024; 14(1):28831.

PMID: 39572602 PMC: 11582715. DOI: 10.1038/s41598-024-78298-2.


GEMA 5.3. Spanish Guideline on the Management of Asthma.

Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G Open Respir Arch. 2023; 5(4):100277.

PMID: 37886027 PMC: 10598226. DOI: 10.1016/j.opresp.2023.100277.


Pediatric asthma pathway in the emergency room.

Lucia D, Cain J, Porter A, Sagar M, Blazovic S, Finley L Proc (Bayl Univ Med Cent). 2021; 34(1):40-43.

PMID: 33456142 PMC: 7785189. DOI: 10.1080/08998280.2020.1801110.


Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study.

Shin J, Yoon H, Lee Y, Ha E, Lee J Sci Rep. 2020; 10(1):18973.

PMID: 33149113 PMC: 7642419. DOI: 10.1038/s41598-020-74854-8.


Developments in asthma incidence and prevalence in Alberta between 1995 and 2015.

Bosonea A, Sharpe H, Wang T, Bakal J, Befus A, Svenson L Allergy Asthma Clin Immunol. 2020; 16:87.

PMID: 33061999 PMC: 7547457. DOI: 10.1186/s13223-020-00485-3.


References
1.
Nowak R, Pensler M, Sarkar D, ANDERSON J, Kvale P, Ortiz A . Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma. Ann Emerg Med. 1982; 11(2):64-9. DOI: 10.1016/s0196-0644(82)80298-9. View

2.
Szczeklik A, Nizankowska E, Dworski R, Domagala B, Pinis G . Cyclosporin for steroid-dependent asthma. Allergy. 1991; 46(4):312-5. DOI: 10.1111/j.1398-9995.1991.tb00590.x. View

3.
Tarlo S, Boulet L, Cartier A, Cockcroft D, Cote J, Hargreave F . Canadian Thoracic Society guidelines for occupational asthma. Can Respir J. 1998; 5(4):289-300. DOI: 10.1155/1998/587580. View

4.
Walshaw M, Evans C . Allergen avoidance in house dust mite sensitive adult asthma. Q J Med. 1986; 58(226):199-215. View

5.
DIXON J . France seeks to curb health costs by fining doctors. BMJ. 1997; 315(7113):895-6. PMC: 2127600. DOI: 10.1136/bmj.315.7113.895. View